Clinical applications of metabolomics in oncology: A review

Jennifer L. Spratlin, Natalie J. Serkova, S. Gail Eckhardt

Research output: Contribution to journalReview article

432 Citations (Scopus)

Abstract

Metabolomics, an omic science in systems biology, is the global quantitative assessment of endogenous metabolites within a biological system. Either individually or grouped as a metabolomic profile, detection of metabolites is carried out in cells, tissues, or biofluids by either nuclear magnetic resonance spectroscopy or mass spectrometry. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect. Despite this, there is lack of knowledge in the oncology community regarding metabolomics and confusion about its methodologic processes, technical challenges, and clinical applications. Metabolomics, when used as a translational research tool, can provide a link between the laboratory and clinic, particularly because metabolic and molecular imaging technologies, such as positron emission tomography and magnetic resonance spectroscopic imaging, enable the discrimination of metabolic markers noninvasively in vivo. Here, we review the current and potential applications of metabolomics, focusing on its use as a biomarker for cancer diagnosis, prognosis, and therapeutic evaluation.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalClinical Cancer Research
Volume15
Issue number2
DOIs
StatePublished - Jan 15 2009

Fingerprint

Metabolomics
Early Detection of Cancer
Molecular Imaging
Translational Medical Research
Systems Biology
Metabolome
Tumor Biomarkers
Positron-Emission Tomography
Mass Spectrometry
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Technology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical applications of metabolomics in oncology : A review. / Spratlin, Jennifer L.; Serkova, Natalie J.; Eckhardt, S. Gail.

In: Clinical Cancer Research, Vol. 15, No. 2, 15.01.2009, p. 431-440.

Research output: Contribution to journalReview article

Spratlin, Jennifer L. ; Serkova, Natalie J. ; Eckhardt, S. Gail. / Clinical applications of metabolomics in oncology : A review. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 2. pp. 431-440.
@article{2fd6ca169202455aa79104e90faad7e5,
title = "Clinical applications of metabolomics in oncology: A review",
abstract = "Metabolomics, an omic science in systems biology, is the global quantitative assessment of endogenous metabolites within a biological system. Either individually or grouped as a metabolomic profile, detection of metabolites is carried out in cells, tissues, or biofluids by either nuclear magnetic resonance spectroscopy or mass spectrometry. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect. Despite this, there is lack of knowledge in the oncology community regarding metabolomics and confusion about its methodologic processes, technical challenges, and clinical applications. Metabolomics, when used as a translational research tool, can provide a link between the laboratory and clinic, particularly because metabolic and molecular imaging technologies, such as positron emission tomography and magnetic resonance spectroscopic imaging, enable the discrimination of metabolic markers noninvasively in vivo. Here, we review the current and potential applications of metabolomics, focusing on its use as a biomarker for cancer diagnosis, prognosis, and therapeutic evaluation.",
author = "Spratlin, {Jennifer L.} and Serkova, {Natalie J.} and Eckhardt, {S. Gail}",
year = "2009",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1059",
language = "English (US)",
volume = "15",
pages = "431--440",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical applications of metabolomics in oncology

T2 - A review

AU - Spratlin, Jennifer L.

AU - Serkova, Natalie J.

AU - Eckhardt, S. Gail

PY - 2009/1/15

Y1 - 2009/1/15

N2 - Metabolomics, an omic science in systems biology, is the global quantitative assessment of endogenous metabolites within a biological system. Either individually or grouped as a metabolomic profile, detection of metabolites is carried out in cells, tissues, or biofluids by either nuclear magnetic resonance spectroscopy or mass spectrometry. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect. Despite this, there is lack of knowledge in the oncology community regarding metabolomics and confusion about its methodologic processes, technical challenges, and clinical applications. Metabolomics, when used as a translational research tool, can provide a link between the laboratory and clinic, particularly because metabolic and molecular imaging technologies, such as positron emission tomography and magnetic resonance spectroscopic imaging, enable the discrimination of metabolic markers noninvasively in vivo. Here, we review the current and potential applications of metabolomics, focusing on its use as a biomarker for cancer diagnosis, prognosis, and therapeutic evaluation.

AB - Metabolomics, an omic science in systems biology, is the global quantitative assessment of endogenous metabolites within a biological system. Either individually or grouped as a metabolomic profile, detection of metabolites is carried out in cells, tissues, or biofluids by either nuclear magnetic resonance spectroscopy or mass spectrometry. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect. Despite this, there is lack of knowledge in the oncology community regarding metabolomics and confusion about its methodologic processes, technical challenges, and clinical applications. Metabolomics, when used as a translational research tool, can provide a link between the laboratory and clinic, particularly because metabolic and molecular imaging technologies, such as positron emission tomography and magnetic resonance spectroscopic imaging, enable the discrimination of metabolic markers noninvasively in vivo. Here, we review the current and potential applications of metabolomics, focusing on its use as a biomarker for cancer diagnosis, prognosis, and therapeutic evaluation.

UR - http://www.scopus.com/inward/record.url?scp=59449097019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449097019&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1059

DO - 10.1158/1078-0432.CCR-08-1059

M3 - Review article

C2 - 19147747

AN - SCOPUS:59449097019

VL - 15

SP - 431

EP - 440

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -